South Korean pharmaceuticals firm Hanall Biopharma Co. is investing in Interon Laboratories, a US biotech firm that finds and develops treatments for brain diseases, the Korean company said on Feb. 10.
The investment will fund Interon's ongoing development of its lead programs targeting a range of neurological and immune disorders.
Interon focuses on developing therapeutics for severe autism spectrum disorder (ASD) by modulating the neuro-immune axis pathway.
Interon will use the technology to proceed with pre-clinical research on developing therapies for neurological disorders, beginning with ASD.
"Interon's innovative approach to treating brain diseases through control of the immune system gives new hope for treating incurable diseases, beyond existing research methods," said Jung Seung-won, CEO of Hanall Biopharma. "We look forward to a range of collaborations with Interon."
Write to Jae-Yong Han at
jyhan@hankyung.com
